Anticancer platinum (IV) prodrugs with novel modes of activity

Current Topics in Medicinal Chemistry

Volumn 11, Issue 21, 2011, Pages 2602-2612

  Chin, Chee Fei ^a   Wong, Daniel Yuan Qiang ^a   Jothibasu, Ramasamy ^a   Ang, Wee Han ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Activation by reduction; Anticancer prodrugs; Cisplatin; Platinum drugs; Targeted delivery

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; IPROPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; PLATINUM IV DERIVATIVE; PRODRUG; SATRAPLATIN; TETRAPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER THERAPY; CELL DEATH; CELL KILLING; CELL VIABILITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ELECTROCHEMICAL ANALYSIS; HUMAN; NONHUMAN; PHOTOTHERAPY; REVIEW; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; NANOTUBES, CARBON; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PHOTOTHERAPY; PLATINUM; PRODRUGS;

EID: 80055087235     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798040778     Document Type: Review

References (97)

1. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699.
2. Rosenberg, B.; Van Camp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds -a new class of potent antitumour agents. Nature, 1969, 222, 385-386.
3. Leonard, B. J.; Eccleston, E.; Jones, D.; Todd, P.; Walpole, A. Antileukaemic and nephrotoxic properties of platinum compounds. Nature, 1971, 234, 43-45.
4. Hoeschele, J. D. In remembrance of barnett rosenberg. Dalton Trans., 2009, 10648-10650.
5. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7, 573-584.
6. Horwich, A.; Shipley, J.; Huddart, R. Testicular germ-cell cancer. Lancet, 2006, 367, 754-765.
7. Keys, H. M.; Bundy, B. N.; Stehman, F. B.; Muderspach, L. I.; Chafe, W. E.; Suggs, C. L.; Walker, J. L.; Gersell, D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med., 1999, 340, 1154-1161.
8. Lévi, F.; Misset, J.-L.; Brienza, S.; Adam, R.; Metzger, G.; Itzakhi, M.; Caussanel, J.-P.; Kunstlinger, F.; Lecouturier, S.; Descorps-Declère, A.; Jasmin, C.; Bismuth, H.; Reinberg, A., A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer, 1992, 69, 893-900.
9. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 2002, 360, 505-515.
10. Jung, Y. W.; Lippard, S. J. Direct cellular responses to platinum-induced DNA damage. Chem. Rev., 2007, 107, 1387-1407.
11. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4, 307-320.
12. Todd, R. C.; Lippard, S. J. Inhibition of transcription by platinum antitumor compounds. Metallomics, 2009, 1, 280-291.
13. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 1999, 99, 2467-2498.
14. Fuertes, M. A.; Alonso, C.; Pérez, J. M. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 2003, 103, 645-662.
15. Kuo, M. T.; Chen, H. H.; Song, I. S.; Savaraj, N.; Ishikawa, T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev., 2007, 26, 71-83.
16. Zhang, S.; Lovejoy, K. S.; Shima, J. E.; Lagpacan, L. L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J. W.; Chen, X.; Lippard, S. J.; Giacomini, K. M. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res., 2006, 66, 8847-57.
17. Galanski, M.; Jakupec, M. A.; Keppler, B. K. Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Curr. Med. Chem., 2005, 12, 2075-2094.
18. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99, 2451-2466.
19. Harrap, K. R. Initiatives with platinum-and quinazoline-based antitumor molecules -Fourteenth Bruce F. Cain memorial award lecture. Cancer Res., 1995, 55, 2761-2768.
20. Sternberg, C. N.; Whelan, P.; Hetherington, J.; Paluchowska, B.; Slee, P. H. T. J.; Vekemans, K.; Van Erps, P.; Theodore, C.; Koriakine, O.; Oliver, T.; Lebwohl, D.; Debois, M.; Zurlo, A.; Collette, L. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 2005, 68, 2-9.
21. McKeage, M. J.; Mistry, P.; Ward, J.; Boxall, F. E.; Loh, S.; O'Neill, C.; Ellis, P.; Kelland, L. R.; Morgan, S. E.; Murrer, B.; Santabarbara, P.; Harrap, K. R.; Judson, I. R. A phase-I and pharmacology study of an oral platinum complex, JM216 -dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother. Pharmacol., 1995, 36, 451-458.
22. Choy, H. Satraplatin: An orally available platinum analog for the treatment of cancer. Expert Rev. Anticancer Ther., 2006, 6, 973-982.
23. Galanski, M.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Recent developments in the field of tumor-inhibiting metal complexes. Curr. Pharm. Des., 2003, 9, 2078-2089.
24. Hall, M. D.; Amjadi, S.; Zhang, M.; Beale, P. J.; Hambley, T. W. The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. J. Inorg. Biochem., 2004, 98, 1614-1624.
25. Dhar, S.; Lippard, S. J. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc. Natl. Acad. Sci. USA, 2009, 106, 22199-22204.
26. Liedert, B.; Pluim, D.; Schellens, J.; Thomale, J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res., 2006, 34, e47.
27. Chen, L.; Lee, P. F.; Ranford, J. D.; Vittal, J. J.; Wong, S. Y. Reduction of the anti-cancer drug analogue cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by L-cysteine and L-methionine and its crystal structure. Dalton Trans., 1999, 1209-1212.
28. Lemma, K.; Sargeson, A. M.; Elding, L. I. Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions. Dalton Trans., 2000, 1167-1172.
29. Hall, M. D.; Mellor, H. R.; Callaghan, R.; Hambley, T. W. Basis for design and development of platinum(IV) anticancer complexes. J. Med. Chem., 2007, 50, 3403-3411.
30. Hall, M. D.; Hambley, T. W. Platinum(IV) antitumour compounds: Their bioinorganic chemistry. Coord. Chem. Rev., 2002, 232, 49-67.
31. Ilangovan, G.; Li, H.; Zweier, J. L.; Kuppusamy, P. In vivo measurement of tumor redox environment using EPR spectroscopy. Mol. Cell. Biochem., 2002, 234-235, 393-398.
32. Stratford, I. J.; Adams, G. E.; Bremner, J. C. M.; Cole, S.; Edwards, H. S.; Robertson, N.; Wood, P. J. Manipulation and exploitation of the tumour environment for therapeutic benefit. Int. J. Radiat. Biol., 1994, 65, 85-94.
33. Galanski, M.; Keppler, B. K. Searching for the magic bullet: Anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med. Chem., 2007, 7, 55-73.
34. Ang, W. H.; Pilet, S.; Scopelliti, R.; Bussy, F.; Juillerat-Jeanneret, L.; Dyson, P. J. Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: Influence of the ligands on drug efficacies and uptake. J. Med. Chem., 2005, 48, 8060-8069.
35. Giandomenico, C. M.; Abrams, M. J.; Murrer, B. A.; Vollano, J. F.; Rheinheimer, M. I.; Wyer, S. B.; Bossard, G. E.; Higgins, J. D. Carboxylation of kinetically inert platinum(IV) hydroxyl complexes -An entree into orally-active platinum(IV) antitumor agents. Inorg. Chem., 1995, 34, 1015-1021.
36. Galanski, M.; Keppler, B. K. Carboxylation of dihydroxoplatinum (IV) complexes via a new synthetic pathway. Inorg. Chem., 1996, 35, 1709-1711.
37. Galanski, M.; Keppler, B. K. Carboxylation of dihydroxoplatinum (IV) complexes with acyl chlorides. Crystal structures of the trans-R,R-and trans-S,S-isomer of (OC-6-33)-bis(1-adamantanecarboxylato)-(cyclohexane-1,2-diamine)dichloroplatinum(IV). Inorg. Chim. Acta, 1997, 265, 271-274.
38. Galanski, M.; Keppler, B. K. Synthesis and characterisation of new ethylenediamine platinum(IV) complexes containing lipophilic carboxylate ligands. Met. Based Drugs, 1995, 2, 57-63.
39. IV(trans-1R,2R-diaminocyclohexane) trans-(acetate)2(9-ethylguanine)Cl]NO3•H2O. J. Inorg. Biochem., 2005, 99, 795-804.
40. Hambley, T. W.; Battle, A. R.; Deacon, G. B.; Lawrenz, E. T.; Fallon, G. D.; Gatehouse, B. M.; Webster, L. K.; Rainone, S. Modifying the properties of platinum(IV) complexes in order to increase biological effectiveness. J. Inorg. Biochem., 1999, 77, 3-12.
41. Khokhar, A. R.; Al Baker, S.; Shamsuddin, S.; Siddik, Z. H. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane) platinum(IV) carboxylate complexes. J. Med. Chem., 1997, 40, 112-116.
42. II(hexamethyleneimine)2(cyclobutanedicarboxylato)]•H2O. Polyhedron, 2002, 21, 2659-2665.
43. Lee, E. J.; Jun, M. J.; Lee, S. S.; Sohn, Y. S. Synthesis, structure, and properties of isopropylidenemalonatoplatinum(IV) complexes. Polyhedron, 1997, 16, 2421-2428.
44. Kelland, L. R.; Murrer, B. A.; Abel, G.; Giandomenico, C. M.; Mistry, P.; Harrap, K. R. Ammine amine platinum(IV) dicarboxylates -A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian-carcinoma cell-lines. Cancer Res., 1992, 52, 822-828.
45. Mistry, P.; Kelland, L. R.; Loh, S. Y.; Abel, G.; Murrer, B. A.; Harrap, K. R. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian-carcinoma cell-lines. Cancer Res., 1992, 52, 6188-6193.
46. Ormerod, M. G.; Orr, R. M.; O'Neill, C. F.; Chwalinski, T.; Titley, J. C.; Kelland, L. R.; Harrap, K. R. The Cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: A flow cytometric study. Br. J. Cancer, 1996, 74, 1935-1943.
47. Orr, R. M.; O'Neill, C. F.; Nicolson, M. C.; Barnard, C. F. J.; Murrer, B. A.; Giandomenico, C. M.; Vollano, J. F.; Harrap, K. R. Evaluation of novel ammine/amine platinum(IV) dicarboxylates in L1210 murine leukemia-cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br. J. Cancer, 1994, 70, 415-420.
48. Kelland, L. R.; Abel, G.; McKeage, M. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Murrer, B. A.; Harrap, K. R. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV) -an orally active platinum drug. Cancer Res., 1993, 53, 2581-2586.
49. [49] Zák, F.; Turánek, J.; Kroutil, A.; Sova, P.; Mistr, A.; Poulová, A.; Mikolin, P.; ák, Z.; Kǎná, A.; Záluská, D.; Neca, J.; indlerová, L.; Kozubik, A. Platinum(IV) complex with adamantylamine as nonleaving amine group: Synthesis, characterization, and In vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J. Med. Chem., 2004, 47, 761-763.
50. Procházka, L.; Turánek, J.; Tesařík, R.; Knotigová, P.; Polášková, P.; Andrysík, Z.; Kozubík, A.; ák, F.; Sova, P.; Neuzil, J.; Machala, M. Apoptosis and inhibition of gap-junctional intercellular communication induced by LA-12, a novel hydrophobic platinum(IV) complex. Arch. Biochem. Biophys., 2007, 462, 54-61.
51. Kozubík, A.; Horváth, V.; Svihálková-Sindlerová, L.; Souček, K.; Hofmanová, J.; Sova, P.; Kroutil, A.; ák, F.; Mistr, A.; Turánek, J. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem. Pharmacol., 2005, 69, 373-383.
52. Turánek, J.; Kašná, A.; Záluská, D.; Neca, J.; Kvardová, V.; Knötigová, P.; Horváth, V.; indlerová, L.; Kozubík, A.; Sova, P.; Kroutil, A.; ák, F.; Mistr, A. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: Comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anti-cancer Drugs, 2004, 15, 537-543.
53. Kozubík, A.; Vaculová, A.; Souček, K.; Vondráček, J.; Turánek, J.; Hofmanová, J. Novel anticancer platinum(IV) complexes with adamantylamine: Their efficiency and innovative chemotherapy strategies modifying lipid metabolism. Met. Based Drugs, 2008, 2008, 417897-417912.
54. Song, R.; Kim, K. M.; Lee, S. S.; Sohn, Y. S. Electrophilic substitution of (diamine)tetrahydroxoplatinum(IV) with carboxylic anhydrides. Synthesis and characterization of (diamine)platinum (IV) complexes of mixed carboxylates. Inorg. Chem., 2000, 39, 3567-3571.
55. Song, R.; Kim, K. M.; Sohn, Y. S. Synthesis and characterization of novel tricarboxylatoplatinum(IV) complexes. Nucleophilic substitution of (diamine)tetrahydroxoplatinum(IV) with carboxylic acid. Inorg. Chim. Acta, 2002, 338, 89-93.
56. Kizu, R.; Nakanishi, T.; Hayakawa, K.; Matsuzawa, A.; Eriguchi, M.; Takeda, Y.; Akiyama, N.; Tashiro, T.; Kidani, Y. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV). Cancer Chemother. Pharmacol., 1999, 43, 97-105.
57. Feazell, R. P.; Nakayama-Ratchford, N.; Dai, H.; Lippard, S. J. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J. Am. Chem. Soc., 2007, 129, 8438-8439.
58. Barnes, K. R.; Kutikov, A.; Lippard, S. J. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol., 2004, 11, 557-564.
59. Perez, J. M.; Camazón, M.; Alvarez-Valdes, A.; Quiroga, A. G.; Kelland, L. R.; Alonso, C.; Navarro-Ranninger, M. C. Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. Chem. Biol. Interact., 1999, 117, 99-115.
60. Alvarez-Valdés, A.; Pérez, J. M.; López-Solera, I.; Lannegrand, R.; Continente, J. M.; Amo-Ochoa, P.; Camazón, M. J.; Solans, X.; Font-Bardía, M.; Navarro-Ranninger, C. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: Circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells. J. Med. Chem., 2002, 45, 1835-1844.
61. Reithofer, M.; Galanski, M.; Roller, A.; Keppler, B. K. An entry to novel platinum complexes: Carboxylation of dihydroxoplatinum (IV) complexes with succinic anhydride and subsequent derivatization. Eur. J. Inorg. Chem., 2006, 2612-2617.
62. Reithofer, M. R.; Schwarzinger, A.; Valiahdi, S. M.; Galanski, M.; Jakupec, M. A.; Keppler, B. K. Novel bis(carboxylato) dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. J. Inorg. Biochem., 2008, 102, 2072-2077.
63. Reithofer, M. R.; Valiahdi, S. M.; Jakupec, M. A.; Arion, V. B.; Egger, A.; Galanski, M.; Keppler, B. K. Novel di-and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J. Med. Chem., 2007, 50, 6692-6699.
64. Mackay, F. S.; Woods, J.; Moseley, H.; Sadler, P. J. Photoactivated platinum(IV) anticancer complexes. Br. J. Dermatol., 2005, 152, 857-858.
65. Kratochwil, N. A.; Zabel, M.; Range, K. J.; Bednarski, P. J. Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: A novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro. J. Med. Chem., 1996, 39, 2499-2507.
66. Kratochwil, N. A.; Bednarski, P. J.; Mrozek, H.; Vogler, A.; Nagle, J. K. Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light. Anticancer Drug Des., 1996, 11, 155-171.
67. Henderson, B. W.; Fingar, V. H. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res., 1987, 47, 3110-3114.
68. DeRosa, M. C.; Crutchley, R. J. Photosensitized singlet oxygen and its applications. Coord. Chem. Rev., 2002, 233-234, 351-371.
69. Mackay, F. S.; Woods, J. A.; Moseley, H.; Ferguson, J.; Dawson, A.; Parsons, S.; Sadler, P. J. A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin. Chem. Eur. J., 2006, 12, 3155-3161.
70. Müller, P.; Schröder, B.; Parkinson, J. A.; Kratochwil, N. A.; Coxall, R. A.; Parkin, A.; Parsons, S.; Sadler, P. J. Nucleotide cross-linking induced by photoreactions of platinum(IV)-azide complexes. Angew. Chem. Int. Ed. Engl., 2003, 42, 349-353.
71. Bednarski, P. J.; Grünert, R.; Zielzki, M.; Wellner, A.; Mackay, F. S.; Sadler, P. J. Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem. Biol., 2006, 13, 61-67.
72. Mackay, F. S.; Woods, J. A.; Heringová, P.; Kašpárková, J.; Pizarro, A. M.; Moggach, S. A.; Parsons, S.; Brabec, V.; Sadler, P. J. A potent cytotoxic photoactivated platinum complex. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 20743-20748.
73. Blanco, N. G.; Maldonado, C. R.; Mareque-Rivas, J. C. Effective photoreduction of a Pt(IV) complex with quantum dots: a feasible new light-induced method of releasing anticancer Pt(II) drugs. Chem. Commun., 2009, 5257-5259.
74. Bakalova, R.; Ohba, H.; Zhelev, Z.; Ishikawa, M.; Baba, Y. Quantum dots as photosensitizers? Nat. Biotechnol., 2004, 22, 1360-1361.
75. He, Q.; Liang, C. H.; Lippard, S. J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. USA, 2000, 97, 5768-5772.
76. Huang, J. C.; Zamble, D. B.; Reardon, J. T.; Lippard, S. J.; Sancar, A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA, 1994, 91, 10394-10398.
77. Ang, W. H.; Khalaila, I.; Allardyce, C. S.; Juillerat-Jeanneret, L.; Dyson, P. J. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc., 2005, 127, 1382-1383.
78. McIlwain, C. C.; Townsend, D. M.; Tew, K. D. Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene, 2006, 25, 1639-1648.
79. Nakajima, T.; Takayama, T.; Miyanishi, K.; Nobuoka, A.; Hayashi, T.; Abe, T.; Kato, J.; Sakon, K.; Naniwa, Y.; Tanabe, H.; Niitsu, Y. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O-1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J. Pharmacol. Exp. Ther., 2003, 306, 861-869.
80. Oakley, A. J.; Lo Bello, M.; Mazzetti, A. P.; Federici, G.; Parker, M. W. The glutathione conjugate of ethacrynic acid can bind to human pi class glutathione transferase P1-1 in two different modes. FEBS Lett., 1997, 419, 32-36.
81. Ang, W. H.; Parker, L. J.; De Luca, A.; Juillerat-Jeanneret, L.; Morton, C. J.; Lo Bello, M.; Parker, M. W.; Dyson, P. J. Rational design of an organometallic glutathione transferase inhibitor. Angew. Chem. Int. Ed. Engl., 2009, 48, 3854-3857.
82. Jaouen, G.; Top, S.; Vessières, A.; Leclercq, G.; McGlinchey, M. J. The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. Curr. Med. Chem., 2004, 11, 2505-2517.
83. Erdreich-Epstein, A.; Shimada, H.; Groshen, S.; Liu, M.; Metelitsa, L. S.; Kim, K. S.; Stins, M. F.; Seeger, R. C.; Durden, D. L. Integrins v 3 and v 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res., 2000, 60, 712-721.
84. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R. A.; Shapiro, L. H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60, 722-727.
85. Mukhopadhyay, S.; Barnés, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug. Chem., 2008, 19, 39-49.
86. Reithofer, M. R.; Valiahdi, S. M.; Galanski, M.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K. Novel endothall-containing platinum(IV) complexes: Synthesis, characterization, and cytotoxic activity. Chem. Biodivers., 2008, 5, 2160-2170.
87. Sodeoka, M.; Baba, Y.; Kobayashi, S.; Hirukawa, N. Structure-activity relationship of cantharidin derivatives to protein phosphatases 1, 2A1, and 2B. Bioorg. Med. Chem. Lett., 1997, 7, 1833-1836.
88. Sutendra, G.; Michelakis, E. D., Reversing the Warburg effect: Metabolic modulation as a novel cancer therapy. In Mitochondria and Cancer, Singh, K. K.; Costello, L. C. Eds. Springer New York, 2009; pp 251-264.
89. Haag, R.; Kratz, F. Polymer therapeutics: Concepts and applications. Angew. Chem. Int. Ed. Engl., 2006, 45, 1198-1215.
90. Yokoyama, M. Drug targeting with nano-sized carrier systems. J. Artif. Organs, 2005, 8, 77-84.
91. Montaña, A. M.; Batalla, C. The rational design of anticancer platinum complexes: The importance of the structure-activity relationship. Curr. Med. Chem., 2009, 16, 2235-2260.
92. Dhar, S.; Liu, Z.; Thomale, J.; Dai, H.; Lippard, S. J. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J. Am. Chem. Soc., 2008, 130, 11467-11476.
93. Dhar, S.; Daniel, W. L.; Giljohann, D. A.; Mirkin, C. A.; Lippard, S. J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J. Am. Chem. Soc., 2009, 131, 14652-14653.
94. Carr, J.; Tingle, M.; McKeage, M. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother. Pharmacol., 2002, 50, 9-15.
95. Rieter, W. J.; Pott, K. M.; Taylor, K. M.; Lin, W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc., 2008, 130, 11584-11585.
96. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA, 2008, 105, 17356-17361.
97. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28, 869-876.